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Objectives.Tocomparethefrequencyofanotherprimarymalignancyinpatientswithdiﬀerentiatedthyroidcarcinoma(DTC)who
received radioiodine therapy or not (131I). Material and Methods. 168 cases of DTC patients were retrospectively evaluated as to the
frequencyof anotherneoplasia bycomparingpatientswith and withoutit,takingintoaccount clinical, laboratory,andtherapeutic
parameters. Results. Another primary malignancy occurred in 8.9% of patients. Of these, 53.3% showed the malignancy before 131I
and 46.7% after it. By comparing both groups, the age at the moment of diagnosis of another neoplasia was 46.1 ± 20.2 years for
the group before 131I therapy and of 69.4 ± 11.4 years for the group after it (P = 0.02). Of the 148 patients treated with 131I, 4.7%
developed another malignancy. The latter were older (61 ± 17 years) than those who did not show another cancer type (44.1 ±
14.2 years) (P<0.05). Conclusion. The frequency of another neoplasia found after 131I was similar to that found before 131I.
1.Introduction
Diﬀerentiated thyroid carcinomas (DTC) are the most fre-
quent malignant endocrine neoplasias [1, 2], and when
properly treated, they show good prognosis and similar life
expectancy to that of the general population [3].
Total thyroidectomy followed by radioiodine ablation
(131I), associated with TSH suppression therapy with
levothyroxine, is the initial treatment recommended for the
majority of patients [4, 5].
T h y r o i da b l a t i o nb y131I fosters the followup of patients
with DTC since it increases serum thyroglobulin speciﬁcity
as a tumor marker. It also fosters early metastasis detection
by means of whole-body scanning (WBS) after an uptake
[6].
Recent studies have reported increased risk for devel-
oping a second cancer after radioiodine therapy [7–9]. On
the other hand, some authors have suggested that patients
with DTC per se show increased incidence of neoplasias
that are unrelated to 131I therapy, thus suggesting another2 ISRN Oncology
common etiology and/or genetic mechanism rather than a
causal relationship [10, 11].
Hence, the present study aimed at evaluating the fre-
quency of another primary malignancy, in addition to DTC,
and its temporal relation to 131I, in patients assisted at a
specialized outpatient unit of a university hospital.
2.MaterialandMethods
The medical records of 168 patients with DTC who initiated
followup at the Thyroid Neoplasia Outpatient Unit of the
Botucatu School of Medicine, UNESP from 1970 to 2008
were retrospectively evaluated.
The following data were obtained: gender, age, age at
the time of thyroidectomy, DTC histological type, follow-up
period, radioiodine therapy performance, accumulated dose
of 131I, presence of a second malignancy, age at its diagnosis,
temporal relationship between the diagnosis of the second
malignancyand 131Idose,andthesecondtypeofmalignancy
presented.
Of the 168 patients, eight were not submitted to 131I, and
12 did not have information about the total 131Id o s e .T h u s ,
the number of patients eﬀectively treated with radioiodine
was 148. They were classiﬁed into two groups (with and
without another neoplasia after 131I use) and then compared
in relation to gender, age at thyroidectomy, histological type
of DTC, follow-up period, accumulated dose of 131I, age at
the diagnosis of another malignancy, and the second type of
malignancy presented.
The patients who developed another neoplasia were
also classiﬁed into two groups: the ﬁrst group showed a
secondmalignancybeforethe 131Idoseandthesecondgroup
showed it after the 131Id o s e .S u c ht w og r o u p sw e r ea l s o
compared with respect to the abovementioned parameters.
2.1.StatisticalAnalysis. Excelsheets(MicrosoftCorporation,
EUA) and the Statistical Analysis System (SAS) software
package,version 9.2, wereusedforstatistical analysis.Results
were expressed in terms of frequencies, mean ± standard
deviation, or median (minimum and maximum values).
Clinical, laboratory, and development data were compared
by using the most appropriate statistical tests to each case.
Student’s t-test for independent samples, the Chi-square test,
and Fisher’s exact test were utilized. Logistic regression, from
which the odds ratio was obtained, and generalized linear
models, with gamma error and a log-link function, were also
ﬁtted.95%conﬁdenceintervalsanda5%levelofsigniﬁcance
(P<0.05) were used.
3. Results
The patients’ general, clinical, epidemiological, and thera-
peutic characteristics, are shown in Table 1. Fifteen patients
(8.9%) showed another neoplasia in addition to DTC. Of
these,eight(53.3%)didnotreceive 131Iorshowedthesecond
malignancy before 131I use, and seven (46.6%) showed it
after 131I therapy. By comparing these two groups, age at the
diagnosis of the second neoplasia was smaller for patients
who developed it before 131I than in the group in which
Table 1: Clinical, epidemiological, and therapeutic characteristics
of 168 patients with diﬀerentiated thyroid carcinoma (DTC).
Clinical, epidemiological, and therapeutic characteristics
Females n (%) Female: 142 (84.7)
Age∗ (years) 45.15 ± 15.32
Follow-up period∗∗ (months) 77.5 (1; 468)
Papilliferous carcinoma n (%) 137 (81.5)
Radioiodine therapy n (%) 160 (95.2)
Radioiodine dose∗∗ (mCi) 200 (30; 870)
Another neoplasia n (%) 15 (8.93)
∗mean ± standard deviation; ∗∗median (minimum value; maximum
value).
another malignancy was observed after radioiodine therapy
(P = 0.02). No signiﬁcant diﬀerences were observed with
respect to gender, age at thyroidectomy, follow-up period, or
histological type of DTC between the two groups (Table 2).
The neoplasias diagnosed before and after 131I therapy
are speciﬁed in Table 3.
Of the 148 patients who received a known accumulated
dose of 131I, seven (4.7%) developed a second malignancy
after treatment. The median time between 131I therapy
and diagnosis of second malignancy was 60 months, with
minimum of 6 months and maximum of 275 months. Age at
thyroidectomy was greater in the group of individuals who
developed another malignancy than in those who did not
show it (P = 0.006). No statistically signiﬁcant diﬀerences
were observed with respect to gender, follow-up period,
accumulated 131I dose, or histological type of DTC between
the two groups (Table 4).
4. Discussion
Theassociationofradioiodinetherapywiththedevelopment
of a second neoplasia in patients with DTC has been
controversial. In our service, the frequency of other primary
n e o p l a s i a sw a s8 . 9 % ,w h i c hi sa na p p a r e n t l yh i g hp e r c e n t a g e
when taking into account that the estimated incidence of
malignant neoplasias for the general population in S˜ ao Paulo
state for the years 2010 and 2011 is approximately 313 per
year for every 100,000 inhabitants [12].
Increased risk for a second neoplasia in patients with
DTC has been reported. Sandeep et al. analyzed over 39,000
patients with thyroid carcinoma and observed 30% risk
increase for developing a second malignancy as compared to
the general population. Additionally, greater occurrence of
thyroid cancer in patients with other types of neoplasias has
been found [8].
In the present study, it was observed that, of the patients
showing another neoplasia, similar percentages had (46.6%)
or had not (53.3%) received a therapeutic dose of 131Ib e f o r e
the other neoplasm. These ﬁndings are in agreement with
those reported by Bhattacharyya et al., who observed that
the use of radioiodine did not increase risk for developing
a second neoplasia by evaluating over 29,000 patients with
DTC [11]. Similarly, Verkooijen et al. observed that the
increased incidence of a second neoplasia was not relatedISRN Oncology 3
Table 2: Clinical and epidemiological characteristics of 15 patients with diﬀerentiated thyroid carcinoma and another malignancy.
Clinical and epidemiological characteristic Another malignancy P
Postiodine
N = 7
(46.66%)
Preiodine
N = 8
(53.33%)
Males N (%) 4 (57.14) 3 (37.5) 0.6193
Age at thyroidectomy (years)∗ 61 ± 17 51 ± 13.7 0.2295
Follow-up period (months)∗∗ 75 (48; 336) 56.5 (20; 60) 0.1505
Age at diagnosis of a second neoplasia∗ (years) 69.4 ± 11.4 46.1 ± 20.2 0.0187
Classic nonpapilliferous histological type N (%) 3 (42.85) 2 (25) 0.6084
∗mean ± standard deviation; ∗∗median (minimum value; maximum value).
Table 3: Types of other neoplasias diagnosed in 15 patients with
diﬀerentiated thyroid carcinoma.
PRE 131I POST 131I
2 breast adenocarcinomas 2 skin spinocellular
carcinomas
1 chronic myeloid leukemia 1 prostate adenocarcinoma
1 lymphoma 1 colon adenocarcinoma
1 rectal adenocarcinoma 1e n d o m e t r i a l
adenocarcinoma
1 Palatal spinocellular
carcinoma 1 rectal carcinoma
1 testicular seminoma 1 lung carcinoma
1e n d o m e t r i a l
adenocarcinoma
to 131I therapy, thus suggesting the nonexistence of a causal
relationship between the two events [10].
Other studies, however, have shown increased risk for
a second malignancy related to radioiodine therapy. In a
prospective study on 6,841 European patients with DTC,
Rubino et al. reported 27% risk for developing a second neo-
plasia,whichisasigniﬁcantincreaseinrelationtothegeneral
population in the studied countries [7]. Those authors
also observed increased risk for both solid tumors and
leukemia, according to the accumulated dose of radioiodine
administered. In 2008, Brown et al. published a prospective
study that followed over 30,000 American patients with
DTC for approximately 103 months and also reported
signiﬁcantly increased risk for a second neoplasia. Such risk
changed according to age at diagnosis and radioactive iodine
use [9]. A recent meta-analysis published in 2009 studied
over 16,000 American and European patients and found
increased risk for developing a second neoplasia in patients
receiving 131I therapy. Such risk was particularly higher for
the development of leukemia and linearly associated with the
accumulated radioiodine dose. However, previous exposure
to 131Itherapywasnotrelatedtoincreasedriskforneoplasias
in the breast, central nervous system, colon, rectum, kidneys,
or stomach of patients with DTC as compared to the general
population [13].
Thediﬀerencesintheﬁndingsfromdiﬀerentstudiesmay
be related to a number of factors, among which are the
particular characteristics of the studied populations. Some
factors, such as genetic proﬁle and environmental character-
istics, certainly inﬂuence the prevalence of diﬀerent types of
cancer. The role played by genetic heredity has been particu-
larly studied. Several loci have recently been associated with
some types of cancer and reported to increase their risk [14].
A study conducted on 9.6 million people found a greater
association with hereditary factors in cancers in the thyroid
(53%), endocrine system (25%), testis (23%), breasts (20%),
and melanoma (20%). However, other types of cancers, such
as those in the nervous system, colon, rectum, non-Hodgkin
lymphoma, and lungs, showed only slight agreement [15]. In
general, the speciﬁc role played by each gene locus in malig-
nancy induction seems to be relatively small [14]. The phe-
nomenon of incomplete alleles of cancer susceptibility and
environmental exposure could be responsible for these ﬁnd-
ings. Hence, depending on the environment, an individual
with high genetic risk for developing a neoplasia may never
show it, while another individual at low risk could eventually
develop it [16, 17]. Among environmental factors, the pos-
sible inﬂuence of disruptors is noteworthy. Exposure to such
elementsseemstoplayanimportantroleintheoccurrenceof
certain cancer types [18]. The group of molecules identiﬁed
as disruptors is heterogeneous and includes synthetic prod-
ucts such as industrial solvents/lubricants and their byprod-
ucts [polychlorinated biphenyls (PCBs), polybrominated
biphenyls (PBBs), dioxins], plastics [bisphenol A (BPA)],
plasticizers (phthalates), pesticides [methoxychlor, chlor-
pyrifos, dichlorodiphenyltrichloroethane (DDT)], fungi-
cides(vinclozolin),andpharmaceuticalagents[diethylstilbe-
strol (DES)]. Natural compounds present in humans as well
as animal foods (e.g., phytoestrogens, including genistein
and coumestrol) can also work as disruptors [19, 20].
Depending on age and exposure time, studies show that
some disruptors can change mechanisms that regulate cell
proliferation and tissue organization patterns, and such
alterations may also be associated with the development of
neoplastic lesions. Disruptors, such as DDT, BPA, DES, seem
to be associated with breast and prostate cancer [21–26].
In addition to the aforementioned factors, which aﬀect
the general population, we could question how much nutri-
tional habits and iodine suﬃciency inﬂuence the occurrence
of other neoplasias, speciﬁcally in patients with DTD treated
by 131I.Theuptakeofiodinebythethyroidtissueismediated4 ISRN Oncology
Table 4: Clinical, epidemiological, and therapeutic characteristics of 148 patients with diﬀerentiated thyroid carcinoma who received a
therapeutic dose of radioactive iodine and showed another postiodine malignancy or not.
Clinical and epidemiological data Another postradioactive iodine malignancy Odds ratio IC 95% P
Yes
N = 7
(4.7%)
No
N = 141
(95.3%)
Males N (%) 4 (57.1) 21 (14.9) 0.123 0.015–1.026 0.0528
Age at thyroidectomy (years)∗ 61 ±17 44.08 ±14.2 1.133 1.036–1.239 0.0061
Follow-up period (months)∗∗ 75 (48; 336) 74 (9; 468) 1.013 1.000–1.026 0.0514
Accumulated dose of 131I( m C i ) ∗∗ 175 (100; 300) 200 (30; 870) 0.994 0.985–1.002 0.1375
Classic nonpapilliferous histological type N (%) 3 (42.8) 59 (41.8) 2.350 0.311–17.742 0.4073
∗mean ± standard deviation; ∗∗median (minimum value; maximum value).
by sodium-iodide symporter (NIS), cloned in 1996 [27].
Although it is classic in the thyroid, NIS is also found
in several other tissues that capture iodine, such as the
stomach, salivary glands, lactating breasts, thymus, nasal
mucosa, lachrymal glands, and placenta [28–30]. While
the NIS-mediated uptake of radioiodine by normal or
neoplastic thyroid cells depends, among other factors, on
the concentration of organiﬁed intracellular iodine [31], the
interferents aﬀecting the uptake of that element in other
organs are not yet known. Since the induction of malignancy
by radioactive iodine must occur through exposure of tissues
to that radiopharmaceutical, the eﬀect of iodine suﬃciency
or deﬁciency on the uptake of 131I in nonthyroid tissues is
questionable. Hence, we may be able to hypothesize that
diﬀerentpopulationswithdiversegeneticandenvironmental
characteristics and diﬀerent iodine suﬃciency could respond
diﬀerentlytoradioactiveiodine withrespecttotheinduction
of another neoplasia.
In this study, the studied characteristics (gender, follow-
up period, histological type, age at diagnosis of another
neoplasia) showed no statistical diﬀerences when comparing
the group that developed a second malignancy before 131I
use and the group that developed another neoplasia after 131I
therapy. The only parameter showing signiﬁcance was age at
diagnosis of another neoplasia.
When comparing the patients who underwent radioio-
dine therapy but did not develop a second neoplasia (141)
to those who were also submitted to 131I and later developed
another malignancy (7), again no diﬀerences were found for
the following studied parameters: gender, follow-up period,
histological type, and accumulated 131I dose. Additionally,
the median accumulated 131I dose in patients who did not
develop a second neoplasia (200mCi) was even higher in
relation to those showing another malignancy (175mCi).
The only parameter that showed statistically signiﬁcant
diﬀerences was age at thyroidectomy, thus suggesting that
older patients at the time of surgery could be at increased
risk for developing a second malignancy. The causes for
this ﬁnding remain to be clariﬁed. With respect to other
primary malignancies found, no predominance of any
speciﬁc neoplasia was observed.
Our study showed limitations, such as its retrospective
character and a short follow-up period (approximately
6.5 years). Moreover, we did not do an active screening of
other cancers, considering the retrospective nature of the
study, such a procedure impractical to monitor all patients
with diﬀerentiated thyroid cancer, which would burden
our health system. Nevertheless, our ﬁndings, as previously
described in other studies, can suggest that, at least in certain
populations, the occurrence of another malignancy after 131I
does not have a causal relationship with such treatment.
Hence, patients with DTC could have increased incidence
of a second neoplasia which is not related to 131I therapy,
thus more probably suggesting a common etiology and/or a
genetic mechanism rather than a causal relationship between
the two tumors.
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